Pharma BD Deal Intelligence
EyeTech is building a strong foundation for success. Their work in basic research on the causes of eye disease and clinical testing of new ophthalmic drugs…
Review of Ophthalmology covered the FDA approval of Macugen by EyeTech/Pfizer for all wet AMD subtypes, framing it as a paradigm shift toward pharmacologic…
Pegaptanib received FDA approval December 2004 as the first anti-angiogenic ophthalmic therapy and first aptamer therapeutic ever approved; Pfizer marketed…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Gilead exclusively licensed NX-1838 (anti-VEGF aptamer) to EyeTech for AMD: $7M upfront and up to $25M development milestones to Gilead. NX-1838 became pegaptanib (Macugen), approved by FDA in 2004 — first anti-VEGF for wet AMD. Strategically notable below $250M threshold; included for historical importance.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license) (this deal) | 2000 | $32M | 47 |
| Johnson & Johnson / Abbott Medical Optics | 2003 | $4.3B | 70 |
| Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) | 2016 | $4.3B | 66 |
| Merck & Co. Inc. / EyeBio Ltd. | 2024 | $3.0B | 61 |
| Viatris / Oyster Point Pharma, Inc. | 2022 | $299M | 58 |
| Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. | 2026 | — | 51 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
← Browse all deals · How we score deals
More: 2000 deals · Ophthalmology deals